Kura Oncology KURA Business Segments
| TTM Q1 '25 | TTM Q4 '24 | TTM Q3 '24 | TTM Q2 '24 | TTM Q1 '24 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| License And Collaboration Revenue | $54.52M+305% | $53.88M— | $40.41M— | $26.94M— | $13.47M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Kura Oncology break its business down?
- Kura Oncology (KURA) reports revenue by product across 3 parts — Development Services For Monotherapy, Development Services In Combination With Other Therapies and License And Collaboration Revenue. Each is extracted from the segment footnotes and tracked over time.
- Where does Kura Oncology's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Kura Oncology's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
